Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C BURNETT

Showing results (731-740 of 921) with videos related to

Pageof 93
Sort By:
Toxins|November 10, 2011
Post-intoxication inhibition of botulinum neurotoxin serotype A within neurons by small-molecule, non-peptidic inhibitorsGordon Ruthel, James C Burnett, Jonathan E Nuss, et al.
Mayo Clinic Proceedings. Innovations, Quality & Outcomes|May 17, 2021
Renal Outcomes in Patients with Systolic Heart Failure Treated With Sacubitril-Valsartan or Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor BlockerNicholas Y Tan, Yihong Deng, Xiaoxi Yao, et al.
Kidney International|May 1, 1995
Urinary endothelin and renal vasoconstriction with cyclosporine or FK506 after liver transplantationS C Textor, J C Burnett, J C Romero, et al.
Journal of Developmental and Behavioral Pediatrics : JDBP|December 17, 2016
Family Functioning and Mood and Anxiety Symptoms in Adolescents Born Extremely PretermAlice C Burnett, Katherine J Lee, Jeanie L Y Cheong, et al.
Plos One|December 29, 2012
CD-NP: a novel engineered dual guanylyl cyclase activator with anti-fibrotic actions in the heartFernando L Martin, S Jeson Sangaralingham, Brenda K Huntley, et al.
British Journal of Pharmacology|April 7, 2020
Cardiorenal syndrome: Multi-organ dysfunction involving the heart, kidney and vasculatureFeby Savira, Ruth Magaye, Danny Liew, et al.
Journal of Cardiac Failure|May 10, 2005
Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST)Mihai Gheorghiade, Cesare Orlandi, John C Burnett, et al.
Arquivos De Neuro-Psiquiatria|December 1, 1995
[Chondromyxoid fibroma of the thoracic spine: a case report and review of the literature]M B Leal Filho, A Pereira Neto, L C Pereira, et al.
Circulation|July 14, 2010
Mineralocorticoid accelerates transition to heart failure with preserved ejection fraction via "nongenomic effects"Selma F Mohammed, Tomohito Ohtani, Josef Korinek, et al.
Risk Analysis : an Official Publication of the Society for Risk Analysis|February 24, 2017
The Economic Impact of Space Weather: Where Do We Stand?J P Eastwood, E Biffis, M A Hapgood, et al.
Pageof 93

Showing results (731-740 of 921) with videos related to

Sort By:
Pageof 93
Toxins|November 10, 2011
Post-intoxication inhibition of botulinum neurotoxin serotype A within neurons by small-molecule, non-peptidic inhibitorsGordon Ruthel, James C Burnett, Jonathan E Nuss, et al.
Mayo Clinic Proceedings. Innovations, Quality & Outcomes|May 17, 2021
Renal Outcomes in Patients with Systolic Heart Failure Treated With Sacubitril-Valsartan or Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor BlockerNicholas Y Tan, Yihong Deng, Xiaoxi Yao, et al.
Kidney International|May 1, 1995
Urinary endothelin and renal vasoconstriction with cyclosporine or FK506 after liver transplantationS C Textor, J C Burnett, J C Romero, et al.
Journal of Developmental and Behavioral Pediatrics : JDBP|December 17, 2016
Family Functioning and Mood and Anxiety Symptoms in Adolescents Born Extremely PretermAlice C Burnett, Katherine J Lee, Jeanie L Y Cheong, et al.
Plos One|December 29, 2012
CD-NP: a novel engineered dual guanylyl cyclase activator with anti-fibrotic actions in the heartFernando L Martin, S Jeson Sangaralingham, Brenda K Huntley, et al.
British Journal of Pharmacology|April 7, 2020
Cardiorenal syndrome: Multi-organ dysfunction involving the heart, kidney and vasculatureFeby Savira, Ruth Magaye, Danny Liew, et al.
Journal of Cardiac Failure|May 10, 2005
Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST)Mihai Gheorghiade, Cesare Orlandi, John C Burnett, et al.
Arquivos De Neuro-Psiquiatria|December 1, 1995
[Chondromyxoid fibroma of the thoracic spine: a case report and review of the literature]M B Leal Filho, A Pereira Neto, L C Pereira, et al.
Circulation|July 14, 2010
Mineralocorticoid accelerates transition to heart failure with preserved ejection fraction via "nongenomic effects"Selma F Mohammed, Tomohito Ohtani, Josef Korinek, et al.
Risk Analysis : an Official Publication of the Society for Risk Analysis|February 24, 2017
The Economic Impact of Space Weather: Where Do We Stand?J P Eastwood, E Biffis, M A Hapgood, et al.
Pageof 93